QuellTX
Sim Tung's work experience began in 2007 at The University of Dundee, where they worked as a Laboratory Demonstrator until January 2008. In January 2008, they joined the National Institute for Medical Research as a Research Technician/Assistant and worked there until September 2013. In September 2013, Sim Tung started their PhD at King's College London and completed it in September 2017. They then worked as a Postdoctoral Researcher at King's College London from October 2017 to April 2019. Sim Tung joined Quell Therapeutics in April 2019 as a Scientist and held that position until March 2021. From April 2021 to May 2022, they worked as a Scientist II at Quell Therapeutics. Currently, Sim Tung is serving as a Senior Scientist at Quell Therapeutics starting from June 2022.
Sim Tung has a Bachelor's Degree in Anatomical and Physiological Sciences from the University of Dundee, which they obtained from 2002 to 2007. Sim then pursued a Master's of Research in Biomedical and Translational Science at King's College London from 2013 to 2014. Subsequently, they continued their education at King's College London, where they earned a Doctor of Philosophy (Ph.D.) in Immunology from 2014 to 2017.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.